ClinicalTrials.gg
Not yet recruitingNCT06856265Updated Mar 4, 2025

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

An interventional study of radiofrequency ablation and Mavacamten in Obstructive Hypertrophic Cardiomyopathy, Mavacamten and Radiofrequency Ablation, sponsored by Shanghai Chest Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Shanghai Chest Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the efficacy and safety of Mavacamten combined with radiofrequency ablation compared to Mavacamten alone in patients with symptomatic obstructive hypertrophic cardiomyopathy (HOCM).

Participants were randomized into two groups:

Read the detailed description

This study aims to evaluate the efficacy and safety of Mavacamten combined with radiofrequency ablation compared to Mavacamten alone in patients with symptomatic obstructive hypertrophic cardiomyopathy (HOCM).

Participants were randomized into two groups:

Group 1: Mavacamten monotherapy Group 2: Mavacamten + Radiofrequency Ablation

02

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy
  • Mavacamten
  • Radiofrequency Ablation
03

In context

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.

Browse Cardiomyopathy, Hypertrophic studies →

Lead sponsor

Shanghai Chest Hospital is the lead sponsor of 198 studies on the registry; 99 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old at screening.
  2. Body weight was greater than 45 kg at screening.
  3. Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) consistent with current American College of Cardiology Foundation/American Heart Association, European Society of Cardiology, and Chinese Society of Cardiology guidelines, ie, satisfy criteria below (criteria to be documented by the echocardiography core laboratory): A. Had unexplained left ventricular (LV) hypertrophy with nondilated ventricular chambers in the absence of other cardiac (eg, hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥15 mm (or ≥13 mm with positive family history of hypertrophic cardiomyopathy), as determined by core laboratory interpretation, and B. Had left ventricular outflow tract (LVOT) peak gradient ≥50 mm Hg during screening as assessed by echocardiography at rest or after Valsalva maneuver (confirmed by echocardiography core laboratory interpretation).
  4. Had documented LV (LVEF) ≥55% by echocardiography core laboratory read of screening TTE at rest.
  5. Had a valid measurement of Valsalva LVOT peak gradient at screening as determined by echocardiography core laboratory.
  6. Had (NYHA) class II or III symptoms at screening.
  7. Had documented oxygen saturation at rest ≥90% at screening.
  8. Study participants were able to understand and comply with the study procedures, understand the risks involved in the study, and provided written according to national, local, and institutional guidelines before the first study-specific procedure.

Exclusion criteria

Exclusion Criteria:

    1. Participated in a clinical trial in which the participant received any drug (or was currently using an investigational device) within 30 days prior to screening, or at least 5 times the respective elimination half-life (if known), whichever was longer.

      1. Known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy. 3) Had a history of syncope within 6 months prior to screening or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening.
      1. Had a history of resuscitated sudden cardiac arrest (at any time) or known history of appropriate implantable cardioverter-defibrillator (ICD) discharge for life-threatening ventricular arrhythmia within 6 months prior to screening.
      1. Had paroxysmal, intermittent atrial fibrillation with atrial fibrillation present per the investigator's evaluation of the participant's (ECG) at the time of screening.
      1. Had persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to screening and/or not adequately rate-controlled within 6 months prior to screening (note: participants with persistent or permanent atrial fibrillation who were anticoagulated and adequately rate-controlled were allowed).
      1. Previously participated in a clinical study with mavacamten. 8) to any of the components of the mavacamten formulation. 9) Current treatment (within 14 days prior to screening) or planned treatment during the study with disopyramide, cibenzoline, or ranolazine. 10) Current treatment (within 14 days prior to screening) or planned treatment during the double blinded treatment with a combination of beta-blockers and verapamil or a combination of beta blockers and diltiazem.
      1. For individuals on beta-blockers, verapamil, or diltiazem, any dose adjustment of that medication within14 days prior to screening or any anticipated change in treatment regimen using these medications during the treatment.
      1. Had been successfully treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation [ASA]) within 6 months prior to screening or planned to have either of these treatments during the study (note: individuals with an unsuccessful myectomy or percutaneous ASA procedure performed >6 months prior to screening were enrolled if study eligibility criteria for LVOT gradient criteria were met).
      1. ICD placement within 2 months prior to screening or planned ICD placement during the study.
      1. Had >500 msec when QRS interval \<120 msec or QTcF >520 msec when QRS ≥120 msec or any other ECG abnormality considered by the investigator to pose a risk to participant safety (eg, second-degree atrioventricular block type II).
      1. Had documented obstructive coronary artery disease (>70% stenosis in 1 or more epicardial coronary arteries) or history of myocardial infarction.
      1. Had known moderate or severe (as per investigator's judgment) aortic valve stenosis, constrictive pericarditis, or congenital heart disease at screening.
      1. Had any acute or serious comorbid condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.
      1. Unable to comply with the study requirements, including the number of required visits to the clinical site.
      1. Pregnant or lactating female.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Mavacamten monotherapy

    Initial Dose: Both groups received a starting dose of Mavacamten 2.5 mg orally once daily. Dose Titration: Adjustments were made based on a previously published titration protocol, guided by correlations among resting left ventricular ejection fraction (LVEF), LVOT gradient during Valsalva maneuver, and pre-dose Mavacamten plasma concentrations. Permitted Doses: Individualized doses included 1 mg, 2.5 mg, 5 mg, 10 mg, or 15 mg.

    Drug: Mavacamten

  • Experimental
    Mavacamten combined with radiofrequency ablation

    Initial Dose: Both groups received a starting dose of Mavacamten 2.5 mg orally once daily. Dose Titration: Adjustments were made based on a previously published titration protocol, guided by correlations among resting left ventricular ejection fraction (LVEF), LVOT gradient during Valsalva maneuver, and pre-dose Mavacamten plasma concentrations. Permitted Doses: Individualized doses included 1 mg, 2.5 mg, 5 mg, 10 mg, or 15 mg. Post-procedure Initiation: In the combination therapy group, Mavacamten was initiated within 24 hours after radiofrequency ablation.

    Procedure: radiofrequency ablation · Drug: Mavacamten

Interventions

  • Procedureradiofrequency ablation

    Radiofrequency Ablation is a minimally invasive interventional technique performed via catheter guidance. It utilizes thermal energy (50-80°C) generated by high-frequency alternating current (typically 300-750 kHz) to induce coagulative necrosis or electrophysiological isolation in targeted tissues, thereby eliminating abnormal electrical activity or mechanical obstruction. In the treatment of cardiomyopathy, RFA is applied to ablate hypertrophied myocardial tissue (e.g., the ventricular septum) to alleviate left ventricular outflow tract (LVOT) obstruction.

  • Initial Dose: Both groups received a starting dose of Mavacamten 2.5 mg orally once daily. Dose Titration: Adjustments were made based on a previously published titration protocol, guided by correlations among resting left ventricular ejection fraction (LVEF), LVOT gradient during Valsalva maneuver, and pre-dose Mavacamten plasma concentrations.

06

What researchers measure

Primary outcomes

  1. Change in Valsalva LVOT peak gradient from baseline to week 30, as determined by Doppler echocardiography.

    Change in Valsalva LVOT peak gradient from baseline to week 30, as determined by Doppler echocardiography.

    Time frame: from baseline to week 30

Secondary outcomes

  1. The proportion of patients at week 30 with a Valsalva LVOT peak gradient less than 30mmHg.

    The proportion of patients at week 30 with a Valsalva LVOT peak gradient less than 30mmHg.

    Time frame: At week 30

  2. The proportion of patients at week 30 with a Valsalva LVOT peak gradient less than 50 mm Hg.

    The proportion of patients at week 30 with a Valsalva LVOT peak gradient less than 50 mm Hg.

    Time frame: At week 30

  3. The proportion of patients at week 30 at least 1 class improvement in NYHA functional classification.

    The proportion of patients at week 30 at least 1 class improvement in NYHA functional classification.

    Time frame: Changes from baseline to week30 in the resting LVOT peak gradient

  4. Changes from baseline to week30 in the resting LVOT peak gradient.

    Changes from baseline to week30 in the resting LVOT peak gradient

    Time frame: from baseline to week 30

  5. Changes from baseline to week 30 in the KCCQ Clinical Summary Score (KCCQ-CSS)

    Changes from baseline to week 30 in the KCCQ Clinical Summary Score (KCCQ-CSS),

    Time frame: from baseline to week 30

  6. Changes from baseline to week 30 in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) level.

    Changes from baseline to week 30 in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) level

    Time frame: from baseline to week 30

  7. Changes from baseline to week 30 in the high-sensitivity cardiac troponin I (hs-cTnI) level.

    Changes from baseline to week 30 in the high-sensitivity cardiac troponin I (hs-cTnI) level.

    Time frame: from baseline to week 30.

  8. Changes from baseline to week 30 left of the ventricular mass index (LVMI) evaluated by CMR imaging.

    Changes from baseline to week 30 left of the ventricular mass index (LVMI) evaluated by CMR imaging.

    Time frame: from baseline to week 30

  9. Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

    Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

    Time frame: from baseline to week 30

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Dec 2025, 9 months later.

Of 47 non-industry interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 9 months is below that.

Counting every sponsor, half of 52 studies reached it within 52 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 4, 2025
StartEst.
Feb 26, 2025
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06856265
Responsible party
Xu Liu (Professor, Shanghai Chest Hospital) — Principal investigator
First posted
Mar 4, 2025
Start date
Feb 26, 2025 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Mar 4, 2025

Study contacts

Mu
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion